Skip to main content

Table 3 Univariate analysis for overall survival (OS), progression-free survival (PFS), and AML transformationa

From: The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts

  OS PFS AML transformation
HR 95 % CI P HR 95 % CI P HR 95 % CI P
Age (>60 years vs. ≤ 60 years) 0.964 0.374–2.487 0.940 1.295 0.516–3.252 0.581 0.924 0.290–2.945 0.893
IPSS-R risk groupsb, higher vs. lower 5.600 1.453–21.583 0.010 5.864 1.186–28.982 0.023    
SF3B1c (mut vs. WT) 1.347 0.261–6.947 0.662 0.452 0.054–3.779 0.684    
U2AF1 (mut vs. WT) 1.167 0.231–5.893 1.000 4.409 1.174–16.558 0.033 0.906 0.106–7.737 1.000
SRSF2 (mut vs. WT) 0.823 0.170–3.989 1.000 3.878 1.181–12.726 0.018 2.864 0.684–11.989 0.151
  1. Statistical significance is indicated by boldface type
  2. aUnivariate analysis of OS, PFS, and AML transformation was performed by two-sided Fisher’s exact test or χ2 test
  3. bIPSS-R higher indicates very high risk or high risk, and IPSS-R lower indicates low risk or very low risk
  4. cFor the IPSS-R lower risk group or SF3B1mut patients, no AML transformation was found
  5. AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; IPSS-R, revised International Prognostic Scoring System; mut, mutated; WT, wild-type